27 clinical trials found.
-
A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
The purpose of the study is to look at safety and tolerability of orally administered CLN-081 monotherapy, as single dose and after multiple doses over ... -
A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial).
You can participate in this study if you are diagnosed with advanced lung cancer. The primary goal of this trial is to evaluate the efficacy ...
-
TH-189: A Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent Advanced Metastatic Non-Small Cell Lung Carcinoma
This study will involve patients who have been diagnosed with non-small cell lung cancer, regardless of the specific type. These patients should have previously received ...
-
A PHASE Ib/II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY ACTIVITY AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WITH A K
This study is for people with advanced or metastatic non-small cell lung cancer (NSCLC) containing a specific KRAS G12C mutation. The study is testing a ...
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ... -
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
This study is designed for patients diagnosed with advanced NSCLC and other solid tumors with an ALK mutation. (NYU-Nuvalent NVL-655)
-
KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
This study will focus on two types of cancer: non-small cell lung cancer and colorectal cancer. The purpose of the study is to find out ...
-
A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors. This is a study for the first time testing of a new medicine called ...
-
RevMed RMC-6236-001: A Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Mutations in KRAS at Position G12.
This study is testing a new medicine, RMC-6236, for patients with certain advanced cancers that have specific changes in a gene called RAS. RMC-6236 aims ...